Chelsea N McMahon1, Kathy Petoumenos2, Karl Hesse3, Andrew Carr3, David A Cooper2,3, Katherine Samaras1,4. 1. Diabetes & Metabolism Division, Garvan Institute of Medical Research, Sydney. 2. Kirby Institute, UNSW Australia, Randwick. 3. HIV, Immunology and Infectious Diseases Unit, St Vincent's Hospital, Sydney. 4. Department of Endocrinology, St Vincent's Hospital, Darlinghurst, NSW, Australia.
Abstract
OBJECTIVE: To determine the long-term incidence of glucose disorders in treated HIV infection, associations with traditional and HIV-specific risk factors. METHODS: Observational cohort of 104 men with treated HIV infection and without diabetes, aged 43 ± 8 years at baseline, with (mean ± SD) 11.8 ± 3.5 years follow-up. Ascertainment of glucose status by fasting glucose or, in a subset (n = 33), a 75 g oral glucose tolerance test by 10-12 years follow-up. A subset underwent sequential body composition measures (n = 58) to determine changes in total body and central abdominal adiposity. RESULTS: The cumulative incidence of glucose disorders was 48.1% (prediabetes 35.6%, diabetes 12.5%), with an incidence rate of 34.5/1000 years of patient follow-up (PYFU) (prediabetes: 24.3/1000 PYFU; diabetes: 10.2/1000 PYFU). Incident glucose disorders were independently associated with higher age (44.9 ± 8.4 vs. 41.1 ± 7.5 years, P = 0.027), baseline C-peptide (2.9 ± 1.3 vs. 2.4 ± 1.1 ng/ml, P = 0.019) and baseline 2-h glucose (135 ± 41 vs. 95 ± 25 mg/dl, P < 0.001). A prior AIDS-defining illness was independently associated with higher follow-up fasting glucose (108 ± 38 vs. 94 ± 16 mg/dl, P = 0.007). Abdominal fat gain over 2-4 years was associated with a 3.16-fold increased risk of incident glucose disorders (95% CI 1.30-7.68, P = 0.011). In a subgroup who underwent further oral glucose tolerance testing, 60% had a glucose disorder, the majority not detected by fasting glucose. CONCLUSION: Men with long-term treated HIV infection have high rates of incident glucose disorders associated with modest abdominal fat gain. Directed measures to prevent diabetes in this population are warranted.
OBJECTIVE: To determine the long-term incidence of glucose disorders in treated HIV infection, associations with traditional and HIV-specific risk factors. METHODS: Observational cohort of 104 men with treated HIV infection and without diabetes, aged 43 ± 8 years at baseline, with (mean ± SD) 11.8 ± 3.5 years follow-up. Ascertainment of glucose status by fasting glucose or, in a subset (n = 33), a 75 g oral glucose tolerance test by 10-12 years follow-up. A subset underwent sequential body composition measures (n = 58) to determine changes in total body and central abdominal adiposity. RESULTS: The cumulative incidence of glucose disorders was 48.1% (prediabetes 35.6%, diabetes 12.5%), with an incidence rate of 34.5/1000 years of patient follow-up (PYFU) (prediabetes: 24.3/1000 PYFU; diabetes: 10.2/1000 PYFU). Incident glucose disorders were independently associated with higher age (44.9 ± 8.4 vs. 41.1 ± 7.5 years, P = 0.027), baseline C-peptide (2.9 ± 1.3 vs. 2.4 ± 1.1 ng/ml, P = 0.019) and baseline 2-h glucose (135 ± 41 vs. 95 ± 25 mg/dl, P < 0.001). A prior AIDS-defining illness was independently associated with higher follow-up fasting glucose (108 ± 38 vs. 94 ± 16 mg/dl, P = 0.007). Abdominal fat gain over 2-4 years was associated with a 3.16-fold increased risk of incident glucose disorders (95% CI 1.30-7.68, P = 0.011). In a subgroup who underwent further oral glucose tolerance testing, 60% had a glucose disorder, the majority not detected by fasting glucose. CONCLUSION:Men with long-term treated HIV infection have high rates of incident glucose disorders associated with modest abdominal fat gain. Directed measures to prevent diabetes in this population are warranted.
Authors: Natalie E Chichetto; Brittanny M Polanka; Kaku A So-Armah; Minhee Sung; Jesse C Stewart; John R Koethe; E Jennifer Edelman; Hilary A Tindle; Matthew S Freiberg Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.495
Authors: Win M Han; Awachana Jiamsakul; Sasisopin Kiertiburanakul; Oon T Ng; Benedict Lh Sim; Ly P Sun; Kinh Van Nguyen; Jun Y Choi; Man P Lee; Wing W Wong; Adeeba Kamarulzaman; Nagalingeswaran Kumarasamy; Fujie Zhang; Junko Tanuma; Cuong D Do; Romanee Chaiwarith; Tuti P Merati; Evy Yunihastuti; Sanjay Pujari; Rossana Ditangco; Suwimon Khusuwan; Jeremy Ross; Anchalee Avihingsanon Journal: J Int AIDS Soc Date: 2019-01 Impact factor: 5.396
Authors: James M Paik; Linda Henry; Pegah Golabi; Saleh A Alqahtani; Gregory Trimble; Zobair M Younossi Journal: Open Forum Infect Dis Date: 2020-01-07 Impact factor: 3.835
Authors: Peter F Rebeiro; Cathy A Jenkins; Aihua Bian; Jordan E Lake; Kassem Bourgi; Richard D Moore; Michael A Horberg; W Christopher Matthews; Michael J Silverberg; Jennifer Thorne; Angel M Mayor; Viviane D Lima; Frank J Palella; Michael S Saag; Keri N Althoff; M John Gill; Cherise Wong; Marina B Klein; Heidi M Crane; Vincent C Marconi; Bryan E Shepherd; Timothy R Sterling; John R Koethe Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999